**Amoxicillin**

**Section:** 6. Anti-infective medicines ➔ 6.2. Antibacterials ➔ 6.2.1. Access group antibiotics

- **Indication:** Infectious cystitis
  - **ICD11 code:** GC80.1

- **INN:** Amoxicillin

- **Medicine type:** Chemical agent

- **Antibiotic groups:** ACCESS

- **List type:** Core

- **Formulations:**
  - Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid (EMLc)
  - Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
  - Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection

- **EML status history:**
  - First added in 2017 (TRS 1006)
  - Removed in 2021

- **Sex:** All

- **Age:** Also recommended for children

- **Therapeutic alternatives:**
  - The recommendation is for this specific medicine

- **Patent information:**
  - Patents have expired in most jurisdictions
  - Read more about patents.

- **Wikipedia:** Amoxicillin

- **DrugBank:** Amoxicillin

---

**Expert Committee recommendation**

The Expert Committee noted the recent data from the Global Antimicrobial Resistance Surveillance System which indicate very high levels of resistance to amoxicillin of E. coli in urinary tract infections, and that for this reason the empiric use of amoxicillin for treatment of lower urinary tract infections is now discouraged in multiple international treatment guidelines. The Committee therefore recommended that the indication of treatment of lower urinary tract infections be removed from the listings of amoxicillin on the EML and EMLc.

---

**Background**

Amoxicillin was recommended as a first-choice treatment option for empiric treatment of lower urinary tract infections in adults and children in 2017, as part of the comprehensive review of antibiotics for common infectious syndromes (1). The EML and EMLc currently include alternative first-choice treatment options for lower urinary tract infection (nitrofurantoin, sulfamethoxazole + trimethoprim, amoxicillin + clavulanic acid, and single-agent trimethoprim).

---

**Public health relevance**

Lower urinary tract infections are very common worldwide and can affect people of any age. According to the Global Burden of Disease study, in 2017 for all ages and both sexes combined, an estimated 274 million new cases of urinary tract infections (lower
Evidence supporting the requested change relies on data from a 2020 report by the Global Antimicrobial Resistance Surveillance System (GLASS) on global antimicrobial resistance (4). GLASS data from 22 countries indicate that a median of 75% (range 45–100%) of Escherichia coli urinary isolates are resistant to amoxicillin. In addition, the empiric use of amoxicillin for treatment of lower urinary tract is explicitly discouraged in multiple guidelines because of high rates of antimicrobial resistance to amoxicillin (5–7). GLASS data are not reported for amoxicillin + clavulanic acid or nitrofurantoin. However, several sources indicate that susceptibility of E. coli in urinary isolates remains generally high, in both adults and children (8–10). GLASS data indicate a median of 55% (range 40–70%) of E. coli urinary isolates are resistant to sulfamethoxazole + trimethoprim (4).

2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and yea
6. Diagnostic et antibiothérapie des infections urinaires bactériennes communautaires de l’adulte [Diagnosis and antibiotic therapy f
9. Sanchez GV, Baird AM, Karlowsky JA, Master RN, Bordon JM. Nitrofurantoin retains antimicrobial activity against multidrug-resis